Adam J. Townsend net worth and biography

Adam Townsend Biography and Net Worth

Adam Townsend joined as our chief commercial officer in November 2018. Prior to joining Apellis, Adam worked at Biogen in Cambridge, Massachusetts, from 2010 until October 2018, with progressive leadership roles in commercial and corporate development. Most recently, Adam served as senior vice president of corporate development. Prior to this, Adam was senior vice president of global marketing and commercial strategy, with global responsibility for the commercial teams involved with all late stage and commercial products. While at Biogen, Adam lead the successful launch of multiple blockbuster products in the neurology and rare disease space. Prior to working at Biogen, Adam held numerous leadership positions with increasing levels of responsibility in Europe: at EUSA Pharma as general manager of the UK, Ireland, and Nordic region and as the head of commercial, driving significant and consistent growth across multiple geographies. Prior to that, Adam worked for Amgen in Zug, Switzerland, as part of Amgen’s European marketing team, and in the UK, where he progressed to be Amgen’s head of marketing. Adam began his career in sales at Novartis UK. Adam received a BSc (Hons) degree in medical biochemistry from the University of London, UK.

What is Adam J. Townsend's net worth?: The estimated net worth of Adam J. Townsend is at least $3.07 million as of February 12th, 2024. Mr. Townsend owns 92,453 shares of Apellis Pharmaceuticals stock worth more than $3,070,364 as of December 21st. This net worth estimate does not reflect any other investments that Mr. Townsend may own. Additionally, Mr. Townsend receives a salary of $770,440.00 as Insider at Apellis Pharmaceuticals. Learn More about Adam J. Townsend's net worth.
How old is Adam J. Townsend?: Mr. Townsend is currently 46 years old. There are 8 older executives and no younger executives at Apellis Pharmaceuticals. The oldest executive at Apellis Pharmaceuticals is Mr. James G. Chopas CPA, VP, Corporate Controller & Chief Accounting Officer, who is 57 years old. Learn More on Adam J. Townsend's age.
What is Adam J. Townsend's salary?: As the Insider of Apellis Pharmaceuticals, Inc., Mr. Townsend earns $770,440.00 per year. There are 3 executives that earn more than Mr. Townsend. The highest earning executive at Apellis Pharmaceuticals is Dr. Cedric Francois M.D., Ph.D., Co-Founder, President, CEO & Director, who commands a salary of $1,440,000.00 per year. Learn More on Adam J. Townsend's salary.
How do I contact Adam J. Townsend?: The corporate mailing address for Mr. Townsend and other Apellis Pharmaceuticals executives is 100 FIFTH AVENUE, WALTHAM MA, 02451. Apellis Pharmaceuticals can also be reached via phone at (617) 977-5700 and via email at [email protected]. Learn More on Adam J. Townsend's contact information.
Has Adam J. Townsend been buying or selling shares of Apellis Pharmaceuticals?: Adam J. Townsend has not been actively trading shares of Apellis Pharmaceuticals during the last quarter. Most recently, Adam J. Townsend sold 1,148 shares of the business's stock in a transaction on Monday, February 12th. The shares were sold at an average price of $67.77, for a transaction totalling $77,799.96. Following the completion of the sale, the insider now directly owns 92,453 shares of the company's stock, valued at $6,265,539.81. Learn More on Adam J. Townsend's trading history.
Who are Apellis Pharmaceuticals' active insiders?: Apellis Pharmaceuticals' insider roster includes Caroline Baumal (Insider), Victoria Brown (Insider), James Chopas (CAO), Mark DeLong (SVP), Pascal Deschatelets (Insider), A. Dunlop (Director), Jeffrey Eisele (Insider), Cedric Francois (CEO), Federico Grossi (Insider), Karen Lewis (Insider), Alec Machiels (Director), Nur Nicholson (Insider), Nicole Perry (VP), Lukas Scheibler (Insider), Timothy Sullivan (CFO), Adam Townsend (Insider), and David Watson (General Counsel). Learn More on Apellis Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Apellis Pharmaceuticals?: During the last twelve months, insiders at the sold shares 30 times. They sold a total of 578,005 shares worth more than $32,477,597.17. The most recent insider tranaction occured on September, 16th when Director A. Sinclair Dunlop sold 37,000 shares worth more than $1,340,510.00. Insiders at Apellis Pharmaceuticals own 6.8% of the company. Learn More about insider trades at Apellis Pharmaceuticals.
Information on this page was last updated on 9/16/2024.

Adam J. Townsend Insider Trading History at Apellis Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/12/2024	Sell	1,148	$67.77	$77,799.96	92,453
1/22/2024	Sell	3,413	$65.00	$221,845.00	94,507
5/3/2023	Sell	5,000	$82.71	$413,550.00	75,995
2/3/2023	Sell	5,000	$55.85	$279,250.00	67,932
1/3/2023	Sell	5,000	$50.70	$253,500.00	42,907
12/5/2022	Sell	5,000	$50.38	$251,900.00	42,907
11/3/2022	Sell	5,000	$58.54	$292,700.00	42,907
8/15/2022	Sell	12,500	$69.00	$862,500.00	42,907
8/11/2022	Sell	12,500	$67.00	$837,500.00	42,907
8/3/2022	Sell	5,000	$56.43	$282,150.00	37,907
7/11/2022	Sell	5,000	$48.42	$242,100.00	42,907

Adam J. Townsend Buying and Selling Activity at Apellis Pharmaceuticals

Apellis Pharmaceuticals Company Overview

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Today's Range

Now: $33.21

$32.89

$34.27

50 Day Range

MA: $30.31

$26.18

$35.42

2 Week Range

Now: $33.21

$24.34

$73.80

Volume

3,733,222 shs

Average Volume

2,007,418 shs

Market Capitalization

$4.13 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.94

Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong

From Brownstone Research | Ad

Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.

Click here to watch this demo and decide for yourself.

Adam Townsend Biography and Net Worth

What is Adam J. Townsend's net worth?

How old is Adam J. Townsend?

What is Adam J. Townsend's salary?

How do I contact Adam J. Townsend?

Has Adam J. Townsend been buying or selling shares of Apellis Pharmaceuticals?

Who are Apellis Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Apellis Pharmaceuticals?